Anders has a rich background in the Life Science industry as Chairman or Board member for prominent companies such as Pelago Bioscience, Vanadis Diagnostics, Cartana, Halo Genomics, Moleculent, Genagon Therapeutics, Fenomark Diagnostics and Epigenica. His expertise extends to pivotal roles, including as Senior Advisor for Business Development at Uppsala Innovation Centre, Chief Financial Officer at Phadia AB, and Vice President Finance and Administration at Pharmacia Canada. Anders also contributes as an investor in Life Science companies through his co-owned company, Colibri Ventures.

Åsa has worked in public and private sector as well as academia and has over ten years of experience in leading positions. She has over twenty years of experience working in the field of clinical microbiology and medical biochemistry and master a wide range of laboratory techniques such as e.g. proteomics, mass spectrometry, imaging, and bioinformatics. At Offspring Biosciences Åsa has the combined responsibility of leading the company as CEO and managing our Operations, HR and Finance.

Dan has over 30 years of experience working with techniques of direct relevance to our company’s service portfolio. He was main responsible for the establishment of a platform for histology-based target validation in neurology at AstraZeneca R&D, Södertälje. This included the build of a bank of animal and human tissues representing various neurological disorders as well as coordinating target validation studies from early pre-clinical phase to clinical trials in phase I. He has worked as department-representative in several drug development projects where he coordinated cross-functional activities across research and therapy areas, reporting to multiple customers and stakeholders. Dan has in-depth understanding of the drug development process in preclinical and early clinical phases and good knowledge of both small and large molecular drug pharmacology.

Anders Dahlstrand brings over 35 years of distinguished experience in academic and pharmaceutical R&D. As a founding member of Offspring Biosciences, he recently transitioned from CEO to CBO to spearhead the company's growth initiatives through strategic business and scientific development while continuing to lead key customer projects. Prior to co-founding Offspring Biosciences, Anders established and led a specialized histopathological analysis unit at AstraZeneca, developing the strategic framework that would later inspire Offspring's service model. His extensive leadership experience spans academic research group management, project leadership, and pharmaceutical industry roles, including positions as Principal Scientist, team leader and core team representative in various management capacities. This combination of scientific expertise and strategic leadership uniquely positions him to drive Offspring's expansion while ensuring delivery of premium histopathological services to the broader scientific community.

Anne has over 30 years of solid experience working with techniques for tissue based analyses in both academic, biotech and CRO settings, including work as Biomedical analyst at the Karolinska and at AstraZeneca R&D. Anne is one of three founders of Offspring, working as Senior Scientist, Functional project lead and Operations Manager until June 2023. She is currently a member to our Board of Director and serves as Senior advisor to our management team.

Mia has over 30 years of working experience with techniques relevant to services offered by Offspring Biosciences. She has worked both in academia, pharmaceutical -, cosmetic - and biotech industry, as well as with sales and marketing in a company which targets clients in the Life Sciences sector. At Offspring Biosciences, Mia is responsible for driving continuous development of our technical capabilities and capacities needed to long term deliver value to our clients. She is also working as a functional project leader in select client projects with responsibility to coordinate execution of studies, as well as to assist the project leader with experimental design and interpretation and reporting of the results.